Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Relmada Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Relmada Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $33.77M, up 13.3% year over year. For fiscal 2025 it was $26.88M, down 41.8% from the year before. The highest annual figure on record is $113.32M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.88M | -41.8% |
| FY2024 | Dec 31, 2024 | $46.18M | -15.7% |
| FY2023 | Dec 31, 2023 | $54.81M | -51.6% |
| FY2022 | Dec 31, 2022 | $113.32M | +25.1% |
| FY2021 | Dec 31, 2021 | $90.62M | +1190.0% |
| FY2019 | Jun 30, 2019 | $7.02M | +138.7% |
| FY2018 | Jun 30, 2018 | $2.94M | +127.5% |
| FY2017 | Jun 30, 2017 | $1.29M | -79.2% |
| FY2016 | Jun 30, 2016 | $6.21M | +18.3% |
| FY2013 | Dec 31, 2013 | $5.25M | – |
| FY2012 | Dec 31, 2012 | -$667.47K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $9.22M | +128.4% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $8.39M | +197.7% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $8.09M | -32.3% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $8.07M | -26.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $4.04M | -63.8% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $2.82M | -73.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $11.95M | -10.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $11.00M | -25.4% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $11.15M | +6.6% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $10.72M | -22.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $13.31M | -16.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $14.75M | -45.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $10.45M | -58.2% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $13.74M | -45.6% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $15.86M | -53.3% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $26.87M | +55.0% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $25.01M | +78.4% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $25.27M | +723.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $33.99M | +2564.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $17.33M | +1278.3% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $14.02M | +886.5% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $3.07M | +220.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.28M | -23.5% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.26M | +734.3% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.42M | +757.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $959.25K | +419.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.67M | +239.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $150.72K | -40.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $165.75K | -54.5% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $184.55K | -69.9% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $490.69K | -19.4% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $254.11K | -88.0% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $364.15K | -87.3% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $613.75K | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $609.12K | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $2.12M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $2.87M | – |
| Q4 FY2013CQ4 2013 | Dec 31, 2013 | -$4.27M | – |
See a number that looks wrong?